RT Journal Article
SR Electronic
T1 Combined cell therapy and anticoagulants for acute respiratory distress syndrome
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 3347
DO 10.1183/13993003.congress-2020.3347
VO 56
IS suppl 64
A1 Marta Camprubí-Rimblas
A1 Aina Areny
A1 Raquel Guillamat-Prats
A1 Luis Morales-Quinteros
A1 Neus Tantinyà
A1 Josep Bringué
A1 Lluís Blanch
A1 Antonio Artigas
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/3347.abstract
AB Background: Recent evidence suggests the beneficial effects of cell therapies and nebulized anticoagulants for acute respiratory distress syndrome (ARDS).Aim: Determine the therapeutic benefit of a combined cell therapy (alveolar type II cells (ATII), mesenchymal stem cells (MSC), supernatant (SN) ATII, SN MSC) with antithrombin in vitro in a coculture of ATII and alveolar macrophages injured with lipopolysaccharide (LPS).Methods: Cocultured ATII and alveolar macrophages isolated from rat lungs were injured with LPS (10 ng/ml). Two hours after the injury a combined cell therapy (ATII, MSC, SN ATII, SN MSC) with antithrombin (0.1 ng/ml) was administered. Proinflammatory mediators and coagulant factors were analyzed via qRT-PCR at 18 h. Data are expressed as mean±SEM. Statistical analysis was performed using One-Way-ANOVA and Bonferroni post-hoc test (statistical significance p≤0.05).Results: Proinflammatory mediators and coagulant factors were significantly increased after LPS administration. After administering the different treatments compared the expression of IL1β, IL6, TF PAI-1 and Plasminogen was not as high as in the LPS group.Conclusions: The results indicate that combined cell therapy with antithrombin are able to attenuate inflammation and coagulation in vitro in a coculture of ATII and macrophages. Both treatments together are able to face different processes involved in lung injury.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3347.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).